Purpose

To investigate the efficacy, safety and tolerability of BI 409306 once daily compared to placebo given for 52 weeks to subjects with attenuated psychosis syndrome.

Category

IRB Number
20180639HU
NCT Number
-
Open to Enrollment
Yes
Sponsor
Boehringer Ingelheim -



Study Contact

Regulatory Point of Contact
Floyd Jones
210-450-3158
jonesfa@uthscsa.edu

Regulatory Point of Contact
Amy Saklad
210-567-8229
saklada@uthscsa.edu

Regulatory Point of Contact
Mary Woolsey
210-567-8049
woolseym@uthscsa.edu



Eligibility

Eligible Ages
16 Years - 30 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

    Exclusion Criteria